Format

Send to

Choose Destination
Neuropharmacology. 2017 Jul 1;120:56-62. doi: 10.1016/j.neuropharm.2016.12.015. Epub 2016 Dec 18.

Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.

Author information

1
Otonomy, 6275 Nancy Ridge Drive, San Diego, 92121, CA, USA. Electronic address: kbishop@otonomy.com.

Abstract

Antisense oligonucleotide (ASO) drugs are an emerging class of therapeutics that have recently demonstrated progress and promise to treat diseases of the central nervous system (CNS). ASOs for a variety of targets and mechanisms are currently being investigated in clinical trials and pre-clinically for a number of CNS diseases. This review examines the available data regarding central ASO delivery, distribution, pharmacokinetics, pharmacodynamics and therapeutic opportunities. This article is part of the Special Issue entitled "Beyond small molecules for neurological disorders".

KEYWORDS:

Antisense oligonucleotides; CNS diseases; Drug development

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center